Search

H Lundbeck A-S

Закрыт

33.78 -2.76

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

33.2

Макс.

36.28

Ключевые показатели

By Trading Economics

Доход

-221M

590M

Продажи

-181M

5.5B

P/E

Средняя по отрасли

12.492

73.239

Прибыль на акцию

1.36

Дивидендная доходность

1.78

Рентабельность продаж

10.648

Сотрудники

5,707

EBITDA

-193M

811M

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

1.78%

3.06%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

38B

Предыдущая цена открытия

36.54

Предыдущая цена закрытия

33.78

H Lundbeck A-S График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 мар. 2025 г., 22:45 UTC

Главные новости

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 мар. 2025 г., 23:54 UTC

Обсуждения рынка

Nikkei May Rise After Monday's Selloff -- Market Talk

31 мар. 2025 г., 23:44 UTC

Обсуждения рынка

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 мар. 2025 г., 23:15 UTC

Обсуждения рынка

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 мар. 2025 г., 23:15 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

31 мар. 2025 г., 22:33 UTC

Главные новости

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 мар. 2025 г., 22:28 UTC

Отчет

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 мар. 2025 г., 22:28 UTC

Отчет

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 мар. 2025 г., 22:28 UTC

Отчет

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 мар. 2025 г., 22:28 UTC

Отчет

China Vanke Swings to Loss for 2024 >000002.SZ

31 мар. 2025 г., 21:47 UTC

Главные новости

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 мар. 2025 г., 21:44 UTC

Главные новости

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 мар. 2025 г., 21:21 UTC

Обсуждения рынка

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 мар. 2025 г., 21:18 UTC

Главные новости

Copper Is 2025's Hottest Commodity -- Update

31 мар. 2025 г., 21:09 UTC

Главные новости

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 мар. 2025 г., 21:02 UTC

Отчет

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 мар. 2025 г., 21:01 UTC

Отчет

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 мар. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

31 мар. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

31 мар. 2025 г., 20:37 UTC

Главные новости

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 мар. 2025 г., 20:17 UTC

Главные новости

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 мар. 2025 г., 20:13 UTC

Главные новости

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 мар. 2025 г., 20:03 UTC

Главные новости

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 мар. 2025 г., 19:09 UTC

Обсуждения рынка

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 мар. 2025 г., 18:56 UTC

Обсуждения рынка

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 мар. 2025 г., 18:54 UTC

Обсуждения рынка

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 мар. 2025 г., 18:40 UTC

Обсуждения рынка

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 мар. 2025 г., 18:34 UTC

Обсуждения рынка

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 мар. 2025 г., 18:28 UTC

Обсуждения рынка

Gold Climbs to Close Out Quarter -- Market Talk

31 мар. 2025 г., 18:03 UTC

Главные новости

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

H Lundbeck A-S Прогноз

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.